Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy

2004 ◽  
Vol 11 (2) ◽  
pp. 153-158 ◽  
Author(s):  
I Taylor ◽  
H Butzkueven ◽  
L Litewka ◽  
L.R MacGregor ◽  
C Szoeke ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Brain Volume ◽  
Lesion Load ◽  
Whole Brain ◽  
Prospective Pilot Study ◽  
Serial Mri

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study

2008 ◽  
Vol 15 (2) ◽  
pp. 204-211 ◽  
Author(s):  
G Tedeschi ◽  
D Dinacci ◽  
M Comerci ◽  
L Lavorgna ◽  
G Savettieri ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
White Matter ◽  
Disease Progression ◽  
Gray Matter ◽  
Brain Atrophy ◽  
Disease Duration ◽  
Lesion Load ◽  
Whole Brain ◽  
Gray Matter Atrophy

Background To investigate in a large cohort of patients with multiple sclerosis (MS), lesion load and atrophy evolution, and the relationship between clinical and magnetic resonance imaging (MRI) correlates of disease progression. Methods Two hundred and sixty-seven patients with MS were studied at baseline and two years later using the same MRI protocol. Abnormal white matter fraction, normal appearing white matter fraction, global white matter fraction, gray matter fraction and whole brain fraction, T2-hyperintense, and T1-hypointense lesions were measured at both time points. Results The majority of patients were clinically stable, whereas MRI-derived brain tissue fractions were significantly different after 2 years. The correlation between MRI data at baseline and their variation during the follow-up showed that lower basal gray matter atrophy was significantly related with higher progression of gray matter atrophy during follow-up. The correlation between MRI parameters and disease duration showed that gray matter atrophy rate decreased with increasing disease duration, whereas the rate of white matter atrophy had a constant pattern. Lower basal gray matter atrophy was associated with increased probability of developing gray matter atrophy at follow-up, whereas gray matter atrophy progression over 2 years and new T2 lesion load were risk factors for whole brain atrophy progression. Conclusions In MS, brain atrophy occurs even after a relatively short period of time and in patients with limited progression of disability. Short-term brain atrophy progression rates differ across tissue compartments, as gray matter atrophy results more pronounced than white matter atrophy and appears to be a early phenomenon in the MS-related disease progression.

scholarly journals Correction to: Whole brain 3D MR fingerprinting in multiple sclerosis: a pilot study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Thomaz R. Mostardeiro ◽  
Ananya Panda ◽  
Norbert G. Campeau ◽  
Robert J. Witte ◽  
Nicholas B. Larson ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Whole Brain

scholarly journals Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis

2022 ◽  
Vol 8 (1) ◽  
pp. 205521732110707
Author(s):  
Satori Ajitomi ◽  
Juichi Fujimori ◽  
Ichiro Nakashima
Keyword(s):  
Multiple Sclerosis ◽  
Processing Speed ◽  
Lateral Ventricle ◽  
Grey Matter ◽  
Brain Volume ◽  
Grey Matter Volume ◽  
Two Dimensional ◽  
Whole Brain ◽  
Brain Volumes ◽  
Matter Volume

Background Two-dimensional (2D) measures have been proposed as potential proxies for whole-brain volume in multiple sclerosis (MS). Objective To verify whether 2D measurements by routine MRI are useful in predicting brain volume or disability in MS. Methods In this cross-sectional analysis, eighty-five consecutive Japanese MS patients—relapsing-remitting MS (81%) and progressive MS (19%)—underwent 1.5 Tesla T1-weighted 3D MRI examinations to measure whole-brain and grey matter volume. 2D measurements, namely, third ventricle width, lateral ventricle width (LVW), brain width, bicaudate ratio, and corpus callosum index (CCI), were obtained from each scan. Correlations between 2D measurements and 3D measurements, the Expanded Disability Status Scale (EDSS), or processing speed were analysed. Results The third and lateral ventricle widths were well-correlated with the whole-brain volume ( p < 0.0001), grey matter volume ( p < 0.0001), and EDSS scores ( p = 0.0001, p = .0004, respectively).The least squares regression model revealed that 78% of the variation in whole-brain volume could be explained using five explanatory variables, namely, LVW, CCI, age, sex, and disease duration. By contrast, the partial correlation coefficient excluding the effect of age showed that the CCI was significantly correlated with the EDSS and processing speed ( p < 0.0001). Conclusion Ventricle width correlated well with brain volumes, while the CCI correlated well with age-independent (i.e. disease-induced) disability.

scholarly journals Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study

Neurology ◽  
2020 ◽  
pp. 10.1212/WNL.0000000000011314
Author(s):  
Robert T Naismith ◽  
Robert A Bermel ◽  
Christopher S Coffey ◽  
Andrew D Goodman ◽  
Janel Fedler ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gray Matter ◽  
Brain Atrophy ◽  
Brain Volume ◽  
Secondary Analysis ◽  
Progressive Multiple Sclerosis ◽  
Whole Brain ◽  
T2 Lesions ◽  
Gray Matter Atrophy ◽  
Inflammatory Processes

OBJECTIVE:For progressive forms of multiple sclerosis, determine whether ibudilast has an effect on brain volume and new lesions.METHODS:A randomized, placebo controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive multiple sclerosis. In this secondary analysis of a previously reported trial, secondary and tertiary endpoints included gray matter atrophy, new or enlarging T2 lesions as measured every 24 weeks, and new T1 hypointensities at 96 weeks. Whole brain atrophy measured by SIENA was a sensitivity analysis.RESULTS:129 participants were assigned to ibudilast and 126 to placebo. New or enlarging T2 lesions were observed in 37.2% on ibudilast and 29.0% on placebo (p=0.82). New T1 hypointense lesions at 96 weeks were observed in 33.3% on ibudilast and 23.5% on placebo (p=0.11). Gray matter atrophy was reduced by 35% for those on ibudilast vs. placebo (p=0.038). Progression of whole brain atrophy by SIENA was slowed by 20% in the ibudilast group compared with placebo (p=0.08).CONCLUSIONS:Ibudilast treatment was associated with a reduction in gray matter atrophy. Ibudilast treatment was not associated with a reduction in new or enlarging T2 lesions, or new T1 lesions. An effect on brain volume contributes to prior data that ibudilast appears to impact markers associated with neurodegenerative processes, but not inflammatory processes.Classification of Evidence:This study provides Class II evidence that for people with MS, ibudilast does not significantly reduce new or enlarging T2 lesions, or new T1 lesions.

scholarly journals Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load

2016 ◽  
Vol 58 (5) ◽  
pp. 467-474 ◽  
Author(s):  
D Pareto ◽  
J Sastre-Garriga ◽  
F X Aymerich ◽  
C Auger ◽  
M Tintoré ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Volume ◽  
Lesion Load ◽  
Regional Brain ◽  
Multiple Sclerosis Patients ◽  
Regional Brain Volume

scholarly journals Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis

2015 ◽  
Vol 26 (1) ◽  
pp. 62-67 ◽  
Author(s):  
Renxin Chu ◽  
Shahamat Tauhid ◽  
Bonnie I. Glanz ◽  
Brian C. Healy ◽  
Gloria Kim ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Healthy Subjects ◽  
Brain Volume ◽  
Whole Brain ◽  
3T Mri

Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty

2019 ◽  
Vol 26 (4) ◽  
pp. 433-441 ◽  
Author(s):  
Margareta A Clarke ◽  
Amal PR Samaraweera ◽  
Yasser Falah ◽  
Alain Pitiot ◽  
Christopher M Allen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Brain Mri ◽  
Central Vein ◽  
Mri Findings ◽  
Median Percentage ◽  
Diagnostic Uncertainty ◽  
Prospective Pilot Study ◽  
Clinical Magnetic Resonance Imaging ◽  
Clinical Diagnoses

Background: Misdiagnosis is common in multiple sclerosis (MS) as a proportion of patients present with atypical clinical/magnetic resonance imaging (MRI) findings. The central vein sign has the potential to be a non-invasive, MS-specific biomarker. Objective: To test the accuracy of the central vein sign in predicting a diagnosis of MS in patients with diagnostic uncertainty at disease presentation using T2*-weighted, 3 T MRI. Methods: In this prospective pilot study, we recruited individuals with symptoms unusual for MS but with brain MRI consistent with the disease, and those with a typical clinical presentation of MS whose MRI did not suggest MS. We calculated the proportion of lesions with central veins for each patient and compared the results to the eventual clinical diagnoses. The optimal central vein threshold for diagnosis was established. Results: Thirty-eight patients were scanned, 35 of whom have received a clinical diagnosis. Median percentage of lesions with central veins was 51% in MS and 28% in non-MS. A threshold of 40.7% lesions with central veins resulted in 100% sensitivity and 73.9% specificity. Conclusion: The central vein sign assessed with a clinically available T2* scan can successfully diagnose MS in cases of diagnostic uncertainty. The central vein sign should be considered as a diagnostic biomarker in MS.

scholarly journals The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis

2017 ◽  
Vol 25 (1) ◽  
pp. 48-54 ◽  
Author(s):  
Alexander Pichler ◽  
Michael Khalil ◽  
Christian Langkammer ◽  
Daniela Pinter ◽  
Stefan Ropele ◽  
...  
Keyword(s):  
Risk Factors ◽  
Multiple Sclerosis ◽  
Brain Volume ◽  
Vascular Risk Factors ◽  
Vascular Risk ◽  
Lesion Load ◽  
Brain Volumes ◽  
Brain Volume Loss ◽  
The Impact

Background: Vascular risk factors (VRF) in multiple sclerosis (MS) patients have been associated with lower brain volumes. It is currently unknown if this association already exists in early MS and how it develops over time. Methods: We identified 82 patients with clinically isolated syndrome (CIS) ( n = 61) or with early relapsing-remitting MS ( n = 21) and assessed their VRF including arterial hypertension, hyperlipidaemia, diabetes mellitus and smoking. We analysed T2-lesion load, normalized brain volume (NBV), cortical grey (cGMV) and white matter volumes (WMV), thalamic and basal ganglia volumes at baseline and follow-up magnetic resonance imaging (MRI) and assessed the percentage of brain volume change (PBVC) using SIENA. Results: Patient mean age was 32.4 (±8.7) years and 54 (65%) were women. Median follow-up period was 42 (29–54) months. In total, 26 patients (31.7%) had one or more VRF (VRF+). At baseline, VRF+ patients had a lower NBV (1530.9 cm3 vs 1591.2 cm3, p = 0.001), a lower cGMV (628.5 cm3 vs 668.6 cm3, p = 0.002) and WMV (752.2 cm3 vs 783.9 cm3, p = 0.009) than VRF-negative patients. Similar results were obtained at follow-up. PBVC was comparable between patients with and without VRF. Conclusion: VRF are associated with lower brain volume already in early MS but do not lead to increased brain volume loss during 3.5 years of follow-up.

Sign in / Sign up

Export Citation Format

Share Document